Pharmacogenomic insights into treatment and management of statin-induced myopathy

Genome Medicine

Volumn 1, Issue 12, 2009, Pages

  Peters, Bas J M ^a   Klungel, Olaf H ^a   Visseren, Frank L ^b   de Boer, Anthonius ^a   Maitland van der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; CARNITINE PALMITOYLTRANSFERASE; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; UBIDECARENONE;

ALLELE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DNA POLYMORPHISM; DRUG WITHDRAWAL; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT HYPERTHERMIA; MUSCLE INJURY; MYALGIA; MYOPATHY; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77956394210     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm120     Document Type: Review

References (27)

1. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002, 33:2337-2341. 10.1161/01.str.0000034125.94759.41, 12215610.
2. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C. 10.1016/j.amjcard.2005.12.010, 16581329.
3. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590. 10.1001/jama.292.21.2585, 15572716.
4. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414. 10.1007/s10557-005-5686-z, 16453090.
5. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007, 29:1761-1770. 10.1016/j.clinthera.2007.08.022, 17919557.
6. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858-868.
7. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmoller J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003, 74:186-194. 10.1016/S0009-9236(03)00121-8, 12891229.
8. Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, Shirai K, Inoue I. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004, 49:582-585. 10.1007/s10038-004-0188-6, 15365880.
9. Ozaki H, Ishikawa CT, Ishii T, Toyoda A, Murano T, Miyashita Y, Shirai K. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. J Clin Pharm Ther 2005, 30:189-192. 10.1111/j.1365-2710.2005.00633_1.x, 15811174.
10. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 2005, 15:415-421. 10.1097/01213011-200506000-00007, 15900215.
11. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007, 17:695-707. 10.1097/FPC.0b013e328012d0a9, 17700359.
12. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008, 84:457-461. 10.1038/clpt.2008.25, 19238649.
13. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007, 8:787-802. 10.2217/14622416.8.7.787, 18240907.
14. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006, 16:873-879. 10.1097/01.fpc.0000230416.82349.90, 17108811.
15. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008, 359:789-799. 10.1056/NEJMoa0801936, 18650507.
16. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1 *5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616. 10.1016/j.jacc.2009.04.053, 19833260.
17. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004, 19:453-455. 10.2133/dmpk.19.453, 15681900.
18. Furihata T, Satoh N, Ohishi T, Ugajin M, Kameyama Y, Morimoto K, Matsumoto S, Yamashita K, Kobayashi K, Chiba K. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J 2009, 9:185-193. 10.1038/tpj.2009.3, 19238167.
19. Fiegenbaum M, da Silveira FR, Sand CR, Sand LC, Ferreira ME, Pires RC, Hutz MH. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005, 78:551-558. 10.1016/j.clpt.2005.08.003, 16321621.
20. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655. 10.1097/BOR.0b013e328314b7b4, 18946323.
21. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006, 34:153-162. 10.1002/mus.20567, 16671104.
22. Haller RG. Treatment of McArdle disease. Arch Neurol 2000, 57:923-924. 10.1001/archneur.57.7.923, 10891971.
23. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006, 166:1519-1524. 10.1001/archinte.166.14.1519, 16864763.
24. Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, Verschuren WM, Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol 2005, 60:83-89. 10.1111/j.1365-2125.2005.02367.x, 1884901, 15963098.
25. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002, 4:45-61. 10.1097/00125817-200203000-00002, 11882781.
26. Peters BJ, Klungel OH, de Boer A, Maitland-van der Zee AH. Genetic determinants of response to statins. Expert Rev Cardiovasc Ther 2009, 7:977-983. 10.1586/erc.09.83, 19673675.
27. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006, 80:356-366. 10.1016/j.clpt.2006.06.010, 17015053.